11 terminated. 11 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Terminated 11 |
| Phase 3 | 1 | Terminated 1 |
Follow Glomerulonephritis, IGA: new trials by email Literature Review of Glomerulonephritis, IGA trials Research Report on Glomerulonephritis, IGA
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of SHR-2010 Injection in the Treatment of Primary IgA Nephropathy SHR-2010 Injection, Placebo - Primary IgA Nephropathy | Phase 2 | Terminated | Guangdong Hengrui Pharmaceutical Co., Ltd | 53 | 2023-06-04 | 2025-03-05 |
| Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN) AT-1501 - IgA Nephropathy, IgAN | Phase 2 | Terminated | Eledon Pharmaceuticals | 24 | 2022-03-21 | 2024-03-26 |
| Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN) BCX9930 - Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy | Phase 2 | Terminated | BioCryst Pharmaceuticals | 2 | 2022-02-18 | 2024-05-02 |
| Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) ALXN2050, Placebo - Lupus Nephritis, Immunoglobulin A Nephropathy | Phase 2 | Terminated | Alexion Pharmaceuticals, Inc. | 100 | 2022-01-14 | 2025-10-15 |
| A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy Telitacicept 160mg, Telitacicept 240mg, Placebo - IgA Nephropathy | Phase 2 | Terminated | RemeGen Co., Ltd. | 15 | 2021-11-04 | 2023-12-06 |
| Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) Ravulizumab, Placebo, Background Therapy - Lupus Nephritis, Immunoglobulin A Nephropathy | Phase 2 | Terminated | Alexion Pharmaceuticals, Inc. | 123 | 2021-01-19 | 2026-01-22 |
| Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy AVB-S6-500 - IgA Nephropathy | Phase 2 | Terminated | Aravive, Inc. | 1 | 2019-11-27 | 2022-02-10 |
| A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN) Placebo, Cemdisiran - IgA Nephropathy (IgAN), Berger Disease | Phase 2 | Terminated | Alnylam Pharmaceuticals | 31 | 2019-09-30 | 2024-08-09 |
| Efficacy and Safety of Atacicept in IgA Nephropathy Placebo, Atacicept 25 mg, Atacicept 75 mg - IgA Nephropathy | Phase 2 | Terminated | EMD Serono Research & Development Institute, Inc. | 16 | 2017-01-31 | 2021-02-25 |
| Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721 OMS721 (narsoplimab) - IgAN, LN | Phase 2 | Terminated | Omeros Corporation | 31 | 2016-03-10 | 2026-03-30 |
| Trial of Plasma Exchange for Severe Crescentic IgA Nephropathy Plasma Exchange (PE), Methylprednisolone pulse - Glomerulonephritis, IGA, Kidney Diseases | Phase 2 / Phase 3 | Terminated | Peking University First Hospital | 10 | 2016-03-01 | 2021-10-08 |
Lupus Nephritis (3) · Proteinuria (3) · Glomerulonephritis (2) · Glomerulonephritis, Membranous (2) · Kidney Diseases (2) · Acute Kidney Injury (1) · Glomerulonephritis, Membranoproliferative (1)
Autoimmune Diseases (11) · Female Urogenital Diseases (11) · Female Urogenital Diseases and Pregnancy Complications (11) · Immune System Diseases (11) · Male Urogenital Diseases (11) · Nephritis (11) · Urogenital Diseases (11) · Urologic Diseases (11) · Glomerulonephritis (9) · Kidney Diseases (9) · Connective Tissue Diseases (3) · Lupus Erythematosus, Systemic (3) · Pathological Conditions, Signs and Symptoms (3) · Signs and Symptoms (3) · Skin and Connective Tissue Diseases (3)
Plasma Exchange (1) · Plasmapheresis (1) · TACI receptor-IgG Fc fragment fusion protein (1) · narsoplimab (1) · ravulizumab (1) · rhoA GTP-Binding Protein (1) · telitacicept (1)
Alexion Pharmaceuticals, Inc. (2) · Alnylam Pharmaceuticals (1) · Aravive, Inc. (1) · BioCryst Pharmaceuticals (1) · EMD Serono Research & Development Institute, Inc. (1) · Eledon Pharmaceuticals (1) · Guangdong Hengrui Pharmaceutical Co., Ltd (1) · Omeros Corporation (1) · Peking University First Hospital (1) · RemeGen Co., Ltd. (1)
United Kingdom (6) · United States (6) · Spain (5) · Australia (3) · China (3) · France (3) · Italy (3) · Taiwan (3) · Canada (2) · Germany (2) · Malaysia (2) · Philippines (2) · Poland (2) · South Korea (2) · Thailand (2)
Carla M Nester, MD, MSA, FASN (1) · Francoise Desir (1) · Hong Zhang, MD, PHD (1)
PMID 38299639, PMID 37528520, PMID 39455063, PMID 39899371
2016 (1), 2018 (1)